Rhythm Pharma's 2024 Executive Compensation & Equity Awards Detailed
Ticker: RYTM · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 1649904
| Field | Detail |
|---|---|
| Company | Rhythm Pharmaceuticals, Inc. (RYTM) |
| Form Type | DEF 14A |
| Filed Date | Apr 29, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, equity-awards, sec-filing, governance
Related Tickers: RYTM
TL;DR
Rhythm Pharma DEF 14A out: Details exec pay, equity awards for 2024. Focus on PEO/Non-PEO compensation structures.
AI Summary
Rhythm Pharmaceuticals, Inc. filed its DEF 14A on April 29, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and equity awards, including fair values of outstanding and unvested equity awards granted during the covered year for both PEO and Non-PEO members. It also outlines adjustments for forfeited awards.
Why It Matters
This filing provides transparency into how Rhythm Pharmaceuticals compensates its top executives and the structure of their equity awards, which can influence company performance and shareholder value.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine disclosures about executive compensation and corporate governance, but can sometimes reveal details about potential compensation-related risks or changes in executive incentives.
Key Numbers
- 2024 — Fiscal Year End (The period covered by the compensation and equity award disclosures.)
- 20250429 — Filing Date (The date Rhythm Pharmaceuticals submitted this DEF 14A filing.)
Key Players & Entities
- RHYTHM PHARMACEUTICALS, INC. (company) — Filer of the DEF 14A
- 0001649904 (company) — Central Index Key for Rhythm Pharmaceuticals
- 20250429 (date) — Filing date of the DEF 14A
- 2024-12-31 (date) — Fiscal year end for the reported period
FAQ
What is the total compensation reported for the named executive officers in 2024?
The provided text does not contain specific dollar amounts for total compensation for named executive officers for 2024. It focuses on the structure and fair value of equity awards.
What were the key performance indicators (KPIs) tied to executive bonuses or equity awards in 2024?
The filing excerpt does not specify the performance indicators used for executive bonuses or equity awards in 2024.
How does the fair value of equity awards granted in 2024 compare to previous years?
This excerpt does not provide comparative data for equity awards granted in years prior to 2024.
What is the distinction between PEO and Non-PEO members in the context of equity awards?
The filing distinguishes between 'PeoMember' and 'NonPeoNeoMember' for equity award valuations, suggesting different categories of executive or employee participation in award programs.
Are there any significant changes in the equity award structure for 2024 compared to 2023?
The provided text focuses on 2024 data and does not offer a direct comparison to the equity award structure in 2023.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 regarding RHYTHM PHARMACEUTICALS, INC. (RYTM).